From global vaccines to personalized cancer therapies, mRNA is being considered across several clinical applications, which ultimately creates varying requirements in terms of production scale and ...

CHARLOTTETOWN, Prince Edward Island & VANCOUVER, British Columbia--(BUSINESS WIRE)--BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service ...

Its proprietary and differentiated lipid nanoparticle (LNP) platform is a cornerstone in advancing next-generation messenger ...

In a recent study published in PNAS, researchers presented a scalable lipid nanoparticle (LNP) production (SCALAR) platform to produce high-throughput lipid nanoparticles on one microfluidic chip and ...

In the dynamic world of mRNA lipid nanoparticle (mRNA-LNP) technology, scientists are quickly moving beyond infectious disease vaccines into a range of new modalities and applications. However, the ...

Product Performance – potency and dosing: Cryogenic transmission electron microscopy (Cryo-TEM) revealed more uniform, solid-core particles. Increased lipid and RNA concentrations can enhance in vivo ...

The success of mRNA vaccines has sparked significant interest and investment in using mRNA technology to treat a broad range of diseases, including cancer, infectious diseases, and rare conditions.

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service agreement under which BIOVECTRA will accept, on a non-exclusive basis, Acuitas’ ...